Latest News

 Filter by Provider

A review and analysis of the precious metals markets.

The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.

Genpact (G) is a quality investment with strong profitability, low debt, and consistent growth. Its solid financial health and reasonable valuation make it ideal for long-term investors.

GLOBALFOUNDRIES Q3 2025 earnings beat EPS estimates with $0.41. Revenue was $1.688B, slightly below forecasts. Strong margins, cash flow, and a solid Q4 outlook highlight disciplined execution.

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.

Improving risk sentiment is boosting the Euro, but it is also holding up the Dollar, so gains here might be limited.

The US dollar has bounced back this morning, and this has kept the EUR/USD under mild pressure, while verbal jawboning in Japan hasn’t helped to stop the yen from sliding to new multi-month lows against the dollar.

Arcos Dorados (ARCO) Q3 2025 earnings beat estimates with a $0.71 EPS, driven by a one-time tax credit, while revenue of $1.19B missed forecasts.

McGraw Hill (MH) Q2 2026 earnings smash EPS estimates. The company raises its full-year profit guidance on strong digital growth and margin expansion.

Clearwater Analytics is exploring a potential sale after receiving takeover interest, as per a Bloomberg report.

Ovid Therapeutics announces CEO succession plan and key pipeline progress for epilepsy drug OV329 and KCC2 activators, backed by a strong cash position.

Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.

CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth.

Innoviz Q3 2025 earnings beat revenue estimates, sees 130% YTD growth, and reaffirms full-year targets, sparking a positive market reaction.

Humacyte (HUMA) missed Q3 revenue estimates but delivered a smaller-than-expected loss per share. The stock rose as investors focused on its pipeline progress toward key regulatory milestones.

Perion Network Q3 2025 earnings smash profit estimates, with EPS of $0.28. Revenue grows 8% to $110.5M, driven by a 75% surge in Connected TV.

Gilat Satellite Networks (GILT) Q3 earnings crush estimates, with EPS nearly doubling forecasts. The strong results sparked a major pre-market rally and prompted raised 2025 guidance.

Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.

Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN.

Prelude Therapeutics beats Q3 2025 earnings estimates, extends cash runway into 2027, and advances its precision oncology pipeline.

Agnico Eagle Mines (AEM) stock shows a powerful mix of strong technical uptrend and accelerating fundamental growth, making it a top pick for momentum investors.

Caesarstone (CSTE) Q3 2025 results show revenue beat estimates, but earnings missed with a wider loss. The company announced a major restructuring to cut costs.

IHS Holding Q3 2025 earnings smash expectations, with EPS 300% above estimates. Strong revenue growth and raised full-year guidance fuel an 18% pre-market stock surge.

Given the number of rules surrounding RMDs, it's easy to make an error.

Super Micro Computer (SMCI) offers strong growth potential in AI and data centers at a reasonable valuation, making it a top affordable growth stock.

The US dollar is mostly consolidating in narrow ranges against the major currencies. The notable exception is the Japanese yen, which has slumped to a new nine-month low as the greenback approached JPY155.

It's an important day for Nvidia shareholders, but the conversation around AI stocks has changed since the company's last earnings report.

Circle Internet Group (CRCL) stock drops after reporting 66% Y/Y revenue growth and beating analyst estimates.

California Gov. Gavin Newsom strongly opposed the Trump's reported intentions to expand offshore drilling in California. The IEA predicted global oil and gas demand could grow until 2050.

United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors.

Check out the companies making headlines yesterday:

Jim Cramer finds Aquestive Therapeutics very interesting, while Amphenol Corporation is a great stock. Joby Aviation is losing money.

Colgate-Palmolive announced its 62nd annual dividend increase this year, but the stock is down 15% so far in 2025.

The GBP/USD pair snapped a four-day winning streak, declining for a second day to trade around 1.3135.

On-chain data from CryptoQuant shows signs of a potential market reset with Bitcoin supply tightening as short-term traders sell at a loss on Binance and longer-term investors accumulate.

Discover how Shoals Technologies (SHLS) fits the Minervini Trend Template, combining a strong technical uptrend with accelerating earnings and sales growth for high-growth momentum investors.

The 401(k) contribution limits are going up in 2026, and it does not make sense for everyone to try to max out their benefit.

Applied Materials, Inc. is expected to report lower quarterly earnings and revenue on Nov. 13. Analysts recommend buying with a $250 target.

It's been a year to forget for these two companies, but brighter days are ahead.

The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.

Discover Atour Lifestyle (ATAT), a strong growth stock with robust fundamentals and a technical breakout setup signaling a potential upward trend.

Italy's industrial stagnation is not over yet, but the picture might improve marginally over the fourth quarter.